Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.
Xenia Androni, Rachel J. Boyd, Paul B. Rosenberg, Vasiliki Mahairaki
Front Dement August 4, 2025 DOI: 10.3389/frdem.2025.1605051 (opens in new tab) via PubMed Central
Summary
AI-generated from the abstractAlzheimer's disease has a long preclinical phase before symptoms appear. Psychedelic compounds show neuroplastogenic and anti-inflammatory effects, making them promising candidates for new Alzheimer's therapies. This mini review summarizes research using human brain organoids to study molecular and metabolic changes caused by psychedelics, focusing on their potential for treating Alzheimer's disease.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Psychedelics psychedelic compounds Psychedelic exposure New therapies Alzheimer's Brain tissue |
| Citations | 4 |
| Key finding | Psychedelic compounds induce neuroplastogenic and anti-inflammatory alterations that may be therapeutically useful for Alzheimer's disease. |
Abstract
Alzheimer's disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induced by these compounds, making them promising therapeutic candidates for AD. In this mini review, we will briefly summarize the existing literature using human cerebral organoids to study the molecular and metabolic changes caused by various psychedelic compounds, focusing on their potential therapeutic applications for AD.